Seeking men and women over 18 years old with HER2 negative gastric cancer for a study comparing chemotherapy plus investigational drugs to chemotherapy alone.
We are studying the effect of the drugs pembrolizumab (pembro), lenvatinib, and chemotherapy, compared to just chemotherapy for the treatment of Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction Adenocarcinoma
What we're hoping for
We hope to determine if the drugs pembrolizumab (pembro) plus lenvatinib plus chemotherapy (chemo) in people with HER2 negative gastric cancer work, are tolerated, and how safe they are, compared to chemotherapy alone.
ClinicalTrials.gov Identifier: NCT04662710